WO1993020820A1 - NEUE VERWENDUNG VON β-CARBOLINEN - Google Patents
NEUE VERWENDUNG VON β-CARBOLINEN Download PDFInfo
- Publication number
- WO1993020820A1 WO1993020820A1 PCT/EP1993/000858 EP9300858W WO9320820A1 WO 1993020820 A1 WO1993020820 A1 WO 1993020820A1 EP 9300858 W EP9300858 W EP 9300858W WO 9320820 A1 WO9320820 A1 WO 9320820A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- hydrogen
- phenyl
- formula
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the invention relates to the new use of ⁇ -carbolines of the formula I and their acid addition salts for the manufacture of a medicament for the symptomatic and preventive treatment of diseases which are based on impaired glutamatergic neurotransmission in the central nervous system, medicaments which contain these compounds and the new compounds of Formula la and the method for producing the same.
- ⁇ -carbolines are characterized by anxiolytic, anticonvulsive, antidepressant, sedative and anti-aggressive effects and also have amnestic or memory-promoting properties.
- NMDA N-methyl-D-aspartate
- KA kainate
- quisqualate quisqualate receptors
- the quisqualate receptors are also called AMPA receptors after the specific agonists (RS) -amino-3-hydroxy-5-methyl-4-isoxazole propionate.
- RS specific agonists
- the quisqualate receptor contains a modulation point that can influence the function of the ion channel, the action on the modulation point of the quisqualate receptor enables bidirectional influencing of the receptor function.
- Clinical and animal experiments indicate that numerous neurological and psychiatric diseases lead to increased or decreased glutamatergic neurotransmission in the CNS.
- Neurodegenerative disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, senile dementia, multi-infarct dementia, amyotrophic lateral sclerosis, epilepsy; Cell damage from hypoglycemia, hypoxia and ischemia; neuronal damage caused by uncontrolled movements; neuronal damage caused by brain damage such as stroke, brain trauma and asphyxia as well
- the compounds of the formula I act on the modulation site of the quisqualate receptor and correct the pathologically modified function of this receptor and can therefore be used for the symptomatic and preventive treatment of the abovementioned diseases.
- R A is hydrogen, halogen, NH 2 , NO 2 , -CHR 1 -R 2 , optionally with halogen,
- R 4 is hydrogen, phenyl, C 3-7 cycloalkyl, C 1-6 alkyl or - (CH 2 ) n -OR 8 and R 9 is hydrogen, C 1-6 alkyl or benzyl, where
- R is hydroxy, C 1-6 alkoxy, benzyloxy or NR 10 R 11 , wherein R 10 and R 11 are the same or different and are hydrogen, C 1-6 alkyl, C 2-6 alkenyl or a saturated atom together with the nitrogen atom 5- or 6-membered heterocycle, which also contain a further sulfur, oxygen or nitrogen atom and can be substituted by phenyl or C 1-4 alkyl, R 1 is hydrogen or C 1-4 alkyl,
- R 2 is hydrogen, C 1-2 alkyl optionally substituted by NR 12 R 13 ,
- Phenyl, benzyl or phenoxy radical R 5 hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl or an optionally substituted phenyl, benzyl, hetaryl or benzo-fused hetaryl radical, R 6 hydrogen, C 1- 6- alkyl or C 2 -6- alkenyl,
- R 7 is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, NR 14 R 15 , hydroxy, C 1-6 alkoxy,
- -CO-R 16 C 3-7 cycloalkyl, an optionally substituted with halogen phenyl or phenyl-C 1-2 alkyl radical. or if necessary with C 1-4 alkoxy, NR 17 R 18 , hydroxy, halogen, phenyl, C 1-4 alkoxycarbonyl or hydroxycarbonyl substituted C 1-6 alkyl and R 6 and R 7 together with the nitrogen atom form a 3 to
- 6-membered saturated heterocycle which can contain a further O or N atom and with one to two C 1-4 alkyl or
- C 1-4 alkoxycarbonyl may be substituted or R 6 and R 7 together with the nitrogen atom form a 5- or
- 6-membered unsaturated heterocycle which can contain one further O or S atom or two further N atoms
- R 8 is hydrogen, C 1-6 alkyl, C 1-4 alkoxy-C 1-4 alkyl or phenyl
- R 12 and R 13 are each hydrogen, phenyl, C 1-4 alkyl or together with the
- Nitrogen atom form a 5- or 6-membered saturated heterocycle which can contain a further O, S or N atom and which can be substituted by one to two C 1-4 alkyl or C 1-4 alkoxycarbonyl, R 14 and R 15 have the meaning of R 12 and R 13 , R 17 and R 18 have the meaning of R 12 and R 13 ,
- R 16 is hydrogen, C 1-4 alkyl or NH 2 and
- n 1, 2 or 3.
- R 9a is C 1-6 alkyl or benzyl
- R A ' is phenyl, hetaryl, -CHR 1 -R 2 , -OR 5 or -CO-R optionally substituted with halogen, C 1-4 -alkyl, C 1-4 -alkoxy or amino and are mono to triple the same or different can and R 1 , R 2 , R 3 , R 4 , R 5 and R have the meaning given above.
- the substituent R A can be in the A ring in position 5-8, preferably in 5-,
- Alkyl contains both straight and branched chain residues such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl and hexyl.
- Cycloalkyl can be used for cyclopropyl. Cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl. If R 5 or R A is a hetaryl radical, this is 5- or 6-membered and contains 1-3 heteroatoms such as nitrogen, oxygen and / or sulfur.
- R 5 is a benzo-condensed hetaryl radical, this contains 1-2 nitrogen atoms such as quinoline, isoquinoline, quinoxaline or benzimidazole.
- the substituent of the phenyl, benzyl and hetaryl radical R can be one to three times in any position. Suitable substituents are halogens, nitro. Cyano, C 1-4 alkyl, C 1-4 alkoxy, amino, C 1-4 alkoxycarbonyl, C 1-4 alkylthio and trifluoromethyl.
- Halogen is to be understood as fluorine, chlorine, bromine or iodine.
- Suitable substituents for the phenyl, benzyl and phenoxy radical R 2 are the substituents of the aramates mentioned for R 5 , in particular halogen.
- phenyl-C 1-2 alkyl examples include benzyl, phenethyl and
- heterocycle contains C 1-4 alkyl groups
- 2,6-dimethylmorpholine and N-methylpiperazine may be mentioned, for example.
- R 6 and R 7 form a 5- or 6-unsaturated heterocycle together with the nitrogen atom, imidazole, pyrrole, pyrazole, for example, are suitable.
- the compounds of the formula I can be in the form of the stereoisomers and mixtures thereof.
- the physiologically compatible acid addition salts are derived from the known inorganic and organic acids, such as, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, formic acid, acetic acid, benzoic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, citric acid, oxalic acid, glyoxylic acid and also, for example, methanesulfonic acid, such as, for example, alkanesulfonic acid, such as, for example, alkanesulfonic acid, Ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and others
- R 7 hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 3-7 cycloalkyl, optionally with Halogen substituted phenyl or phenyl-C 1-2 -alkyl radical, or - optionally with C 1-4 -alkoxy, NR 17 R 18 .
- R 4 is in particular hydrogen, C 1-6 alkyl or
- the compounds of the formula Ia can be prepared in the same way as the previously known ⁇ -carbolines by using a compound of the formula II
- R A ' , R 4 and R 3 have the abovementioned meaning, optionally after protecting hydroxyl groups, with R 9a X, in which X is halogen, tosylate,
- Mesylate or triflate means alkylated and optionally present
- Solvents such as methylene chloride, dimethyl sulfoxide, dimethylformamide or tetrahydrofuran are preferred as solvents for the homogeneous reactions and those taking place under solid-liquid phase transfer, while methylene chloride, benzene or toluene can be used in the case of liquid-liquid phase transfer reactions.
- a catalyst such as tetrabutylammonium hydrogensulfate or Aliquat 336 advantageous.
- Suitable protective groups that are not attacked under the reaction conditions.
- Examples of such protective groups are for
- Aromatic hydroxyl protecting groups benzyl, methoxymethyl
- Trialkylsilyl groups for the carboxyl groups alkyl esters, benzyl esters or tert-butyl esters.
- the protective groups can optionally be removed when the reaction mixture is worked up.
- Mineral acids and organic acids and their mixtures or tetrabutylammonium fluoride are suitable for acidic cleavages.
- Benzyl residues are usually catalytically hydrogenated e.g. with palladium / coal.
- Alkyl esters can be hydrolyzed under alkaline conditions.
- the isomer mixtures can be separated into the diastereomers or enantiomers by customary methods such as, for example, crystallization, chromatography or salt formation.
- a compound of the formula I is dissolved, for example, in a little alcohol and mixed with a concentrated solution of the desired acid.
- the starting compounds of the formula II are obtained, for example, by hydrolysis of the ⁇ -carboline-3-carboxylic acid alkyl esters, followed by amidation of the free carboxylic acid, if appropriate after conversion into a reactive acid derivative.
- the ⁇ -carboline-3-carboxylic acids are prepared by customary acidic or alkaline hydrolysis, for example using aqueous alkali or alkaline earth metal solutions, optionally with the addition of organic solvents such as alcohols at temperatures from room temperature to 150 ° C.
- the amidation takes place on the free carboxylic acids or on their reactive derivatives such as, for example, acid chlorides, mixed anhydrides, imidazolides or azides by reaction with the corresponding amines at room temperature. If disubstituted amides are to be prepared, the reaction is advantageously carried out with the corresponding formamides at temperatures of 100-220 ° C.
- mice weighing 18-22g were kept under controlled conditions (6 a.m. - 6 p.m. light / dark rhythm, with free access to food and water) and their assignment to groups was randomized.
- the groups consisted of 5-16 animals. The animals were observed between 8 a.m. and 1 p.m.
- Quisqualate was injected into the left ventricle by freely moving mice.
- the applicator consisted of a cannula with a stainless steel device that limits the depth of the injection to 3.2 mm.
- the applicator was connected to an injection pump.
- the injection needle was inserted perpendicular to the surface of the skull according to the coordinates of Montemurro and Dukelow.
- the animals were observed for up to 180 seconds until clonic or tonic cramps occurred.
- the clonic movements that lasted longer than 5 seconds were counted as convulsions.
- the beginning of the clonic convulsions was used as the end point for the determination of the convulsive threshold.
- the dose required to increase or decrease the seizure threshold by 50% (THRD) was determined in 4-6 experiments.
- the THRD 50 and the confidence limit were determined in a regression analysis.
- the table below shows the example of 5-isopropoxy-4-methyl-9-methyl-ß-carboline-3-carboxylic acid ethyl ester (A) and the example of 5-isopropoxy-4-methyl-ß-carboline-3-carboxylic acid ethyl ester (B ) that the cramp threshold for quisqualate is increased (+) or decreased (-).
- the compounds of formula I and their acid addition salts are suitable for the treatment of diseases which arise as a result of disorders in the glutamate-mediated neurotransmission. Treatment with ⁇ -carbolines prevents or delays the cell damage and functional disorders that occur as a result of the disease and reduces the symptoms that result.
- ⁇ -Carbolines of the formula I are suitable according to the invention for producing a medicament for the treatment of neurological diseases which are based on neurodegenerative disorders such as Parkinson's disease, amyotrophic lateral sclerosis.
- the compounds of the formula I are also suitable for the treatment of psychiatric disorders such as schizophrenia, migraines and pain and for the treatment of withdrawal symptoms after drug abuse (opiates, hallucinogens, sedative drugs, alcohol and cocaine).
- the indications can be shown by conventional pharmacological tests.
- the invention also encompasses pharmaceutical compositions which contain the compounds mentioned, their preparation and the use of the compounds according to the invention for the preparation of medicaments which are used for the treatment and prophylaxis of the abovementioned diseases.
- the pharmaceuticals are produced by methods known per se by bringing the active ingredient into the form of a pharmaceutical preparation with suitable carriers, auxiliaries and / or additives, which is suitable for enteral or parenteral administration.
- the application can take place orally or sublingually as a solid in the form of capsules or tablets or as a liquid in the form of solutions, suspensions, elixirs or emulsions or rectally in the form of suppositories or in the form of injection solutions which may also be used subcutaneously.
- auxiliaries for the desired pharmaceutical formulation are the inert organic and inorganic carrier materials known to the person skilled in the art, such as, for example, water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
- preservatives, stabilizers , Wetting agents, emulsifiers or salts to change the osmotic pressure or buffers may be included.
- the pharmaceutical preparations can be in solid form, for example as tablets, dragées, suppositories, capsules or in liquid form, for example as solutions, suspensions or emulsions.
- Auxiliaries close to the surface such as salts of bile acids or animal or vegetable phospholipids, but also mixtures thereof and liposomes or their components can also be used as carrier systems.
- tablets coated tablets or capsules with talc and / or hydrocarbon carriers or binders, such as
- Example lactose corn or potato starch, suitable. They can also be used in liquid form, for example as juice, to which a sweetener may be added.
- Injection solutions or suspensions in particular aqueous solutions of the active compounds in polyhydroxyethoxylated castor oil, are particularly suitable for parenteral use.
- the dosage of the active ingredients can vary depending on the type of application, age and weight of the patient, type and severity of the disease to be treated and similar factors.
- the daily dose can be given as a single dose to be administered once or divided into 2 or more daily doses.
- the compounds are introduced in a dose unit of 0.05 to 100 mg of active substance in a physiologically acceptable carrier. Generally, a dose of 0.1-500 mg / day, preferably 0.1-50 mg / day, is used.
- the compounds of the formula I are known or can be prepared analogously to known compounds and known processes.
- the preparation of the compounds of the formula is described in the following protective rights: EP-30254, EP-54507, EP-128415, EP-130140, EP-130141, EP-137390, EP-161575, EP-222693, EP-234173, EP -232675, EP-237467, WO 92/21679 and DOS-4130933.2.
- a suspension of 724 mg (2 mmol) of 5-benzyloxy-4-methoxymethyl-ß-carboline-3-carboxylic acid is mixed in 29 ml of absolute dimethylformamide with 32 ml of a 0.25 molar solution of thionylimidazole in tetrahydrofuran and stirred for 2 hours at room temperature .
- a clear solution was then created. 100 ml of water are added and the mixture is extracted three times with ethyl acetate. The organic phase is washed with saturated sodium chloride solution, dried, filtered and concentrated.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5517954A JPH07505404A (ja) | 1992-04-10 | 1993-04-06 | β−カルボリンの新規使用 |
EP93908924A EP0633779A1 (de) | 1992-04-10 | 1993-04-06 | NEUE VERWENDUNG VON $g(b)-CARBOLINEN |
NO943793A NO943793L (no) | 1992-04-10 | 1994-10-07 | Ny anvendelse av |
FI944714A FI944714A (fi) | 1992-04-10 | 1994-10-07 | Beta-karboliinien uusi käyttö |
KR1019940703566A KR950700739A (ko) | 1992-04-10 | 1994-10-08 | β-카르볼린의 새로운 용도(New Use of β-Carbolines) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4212529.4 | 1992-04-10 | ||
DE4212529A DE4212529A1 (de) | 1992-04-10 | 1992-04-10 | Verwendung von µ-Carbolinen als nicht-kompetitive Glutamat-Antagonisten |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993020820A1 true WO1993020820A1 (de) | 1993-10-28 |
Family
ID=6456829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1993/000858 WO1993020820A1 (de) | 1992-04-10 | 1993-04-06 | NEUE VERWENDUNG VON β-CARBOLINEN |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0633779A1 (de) |
JP (1) | JPH07505404A (de) |
KR (1) | KR950700739A (de) |
CA (1) | CA2117755A1 (de) |
DE (1) | DE4212529A1 (de) |
FI (1) | FI944714A (de) |
HU (1) | HUT68212A (de) |
IL (1) | IL105349A0 (de) |
WO (1) | WO1993020820A1 (de) |
ZA (1) | ZA932553B (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995006647A1 (de) * | 1993-08-31 | 1995-03-09 | Schering Aktiengesellschaft | ALKOXY-SUBSTITUIERTE β-CARBOLINE MIT EINWIRKUNG AUF DEN AMPA-REZEPTOR |
WO1997015225A1 (fr) * | 1995-10-23 | 1997-05-01 | Nikolai Serafimovich Zefirov | Agent therapeutique contre les troubles neurodegeneratifs |
WO2006133391A2 (en) * | 2005-06-06 | 2006-12-14 | Fibrogen, Inc. | Improved treatment for anemia using a hif-alpha stabilising agent |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4436190A1 (de) * | 1994-10-10 | 1996-04-11 | Gerhard Prof Dr Bringmann | Halogenierte ß-Carbolin-Derivate, Verfahren zu ihrer Herstellung und Verwendung dieser Substanzen zur Hemmung der Atmungskette |
US5824662A (en) | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
AU733880B2 (en) | 1996-09-27 | 2001-05-31 | Eisai Inc. | Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0222693A2 (de) * | 1985-11-13 | 1987-05-20 | Schering Aktiengesellschaft | Neue 3-Oxadiazol- und 3-Carbonsäure-beta-Carbolinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
EP0232675A1 (de) * | 1985-12-20 | 1987-08-19 | Schering Aktiengesellschaft | 5-Aminoalkyl-Beta-Carbolinderivate, ihre Herstellung und Verwendung als Arzneimittel |
-
1992
- 1992-04-10 DE DE4212529A patent/DE4212529A1/de not_active Withdrawn
-
1993
- 1993-04-06 EP EP93908924A patent/EP0633779A1/de not_active Withdrawn
- 1993-04-06 CA CA002117755A patent/CA2117755A1/en not_active Abandoned
- 1993-04-06 WO PCT/EP1993/000858 patent/WO1993020820A1/de not_active Application Discontinuation
- 1993-04-06 JP JP5517954A patent/JPH07505404A/ja active Pending
- 1993-04-06 HU HU9402925A patent/HUT68212A/hu unknown
- 1993-04-08 ZA ZA932553A patent/ZA932553B/xx unknown
- 1993-04-09 IL IL105349A patent/IL105349A0/xx unknown
-
1994
- 1994-10-07 FI FI944714A patent/FI944714A/fi not_active Application Discontinuation
- 1994-10-08 KR KR1019940703566A patent/KR950700739A/ko not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0222693A2 (de) * | 1985-11-13 | 1987-05-20 | Schering Aktiengesellschaft | Neue 3-Oxadiazol- und 3-Carbonsäure-beta-Carbolinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
EP0232675A1 (de) * | 1985-12-20 | 1987-08-19 | Schering Aktiengesellschaft | 5-Aminoalkyl-Beta-Carbolinderivate, ihre Herstellung und Verwendung als Arzneimittel |
Non-Patent Citations (7)
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995006647A1 (de) * | 1993-08-31 | 1995-03-09 | Schering Aktiengesellschaft | ALKOXY-SUBSTITUIERTE β-CARBOLINE MIT EINWIRKUNG AUF DEN AMPA-REZEPTOR |
WO1997015225A1 (fr) * | 1995-10-23 | 1997-05-01 | Nikolai Serafimovich Zefirov | Agent therapeutique contre les troubles neurodegeneratifs |
WO2006133391A2 (en) * | 2005-06-06 | 2006-12-14 | Fibrogen, Inc. | Improved treatment for anemia using a hif-alpha stabilising agent |
WO2006133391A3 (en) * | 2005-06-06 | 2007-08-02 | Fibrogen Inc | Improved treatment for anemia using a hif-alpha stabilising agent |
Also Published As
Publication number | Publication date |
---|---|
DE4212529A1 (de) | 1993-10-14 |
JPH07505404A (ja) | 1995-06-15 |
KR950700739A (ko) | 1995-02-20 |
ZA932553B (en) | 1993-11-02 |
CA2117755A1 (en) | 1993-10-11 |
HU9402925D0 (en) | 1995-01-30 |
IL105349A0 (en) | 1993-08-18 |
FI944714A0 (fi) | 1994-10-07 |
FI944714A (fi) | 1994-10-07 |
HUT68212A (en) | 1995-06-28 |
EP0633779A1 (de) | 1995-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0338331A1 (de) | 1,3-Disubstituierte Pyrrolidine | |
DE10023485A1 (de) | Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel | |
EP0888313A1 (de) | 2,3-benzodiazepinderivate und deren verwendung als ampa-rezeptoren-hemmer | |
DE69720021T2 (de) | 1,4-disubstituierte piperazine | |
WO1993020820A1 (de) | NEUE VERWENDUNG VON β-CARBOLINEN | |
CH619462A5 (en) | Process for the preparation of novel piperazinylpyrazines | |
WO1992014465A1 (de) | Verwendung von anellierten tetrahydropyridinessigsäurederivaten für die behandlung neurologischer erkrankungen | |
EP0775143B1 (de) | 3-substituierte 3h-2,3-benzodiazepinderivate, deren herstellung und verwendung als arzneimittel | |
EP0180834B1 (de) | 4-Alkoxy-pyrido[2,3-d]pyrimidin-Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
DE2802453C3 (de) | Derivate des 3-[(3-Alkyl-5-isochinolyl)-imino]-1,5,10,10a-tetrahydro-thiazolo [3,4-b]isochinolins, ihre Herstellung und die sie enthaltenden Zusammensetzungen | |
DE69827614T2 (de) | Chinoxalindionen | |
EP0993458B1 (de) | 3-benzylpiperidine | |
EP0173933A1 (de) | 1,6-Naphthyridin-Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
DE19617863A1 (de) | Phthalazinderivate, deren Herstellung und Verwendung als Arzneimittel | |
EP0180833B1 (de) | 4-Oxo-pyrido[2,3]pyrimidin-Derivate, Verfahren zur deren Herstellung und diese ethaltende Arzneimittel | |
EP0138034B1 (de) | Substituierte Pyrido(1,2-c)imidazo((1,2-a)benzimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung sowie pharmazeutische Präparate auf Basis dieser Verbindungen | |
EP0088323B1 (de) | Imidazothiadiazolalkencarbonsäureamide, neue Zwischenprodukte zu ihrer Herstellung, ihre Herstellung und ihre Verwendung in Arzneimitteln | |
DE19617862A1 (de) | Phthalazinderivate, deren Herstellung und Verwendung als Arzneimittel | |
EP0696291B1 (de) | Pyrido 1,2,3-de]chinoxalinderivate, verfahren zu deren herstellung und ihre verwendung in arzneimitteln | |
DE2308064C3 (de) | Benzotriazole, ihre Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
WO1995006647A1 (de) | ALKOXY-SUBSTITUIERTE β-CARBOLINE MIT EINWIRKUNG AUF DEN AMPA-REZEPTOR | |
EP0993461A1 (de) | Chinoxalindionderivate als ampa-rezeptor-antagonisten | |
DE3943180A1 (de) | Cyclische guanidin-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel | |
DE4223164A1 (de) | 9-carbamoyl-(beta)-carboline, deren herstellung und verwendung in arzneimitteln | |
DE19905254A1 (de) | Piperidin- und Pyrrolidin-Derivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA FI HU JP KR NO |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993908924 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2117755 Country of ref document: CA Ref document number: 944714 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1993908924 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993908924 Country of ref document: EP |